References
- Coleman R E. Bisphosphonates: Clinical experience. The Oncologist 2004; 9(suppl 4)14–27
- Rosen L S, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735–44
- Rosen L S, Gordon D H, Dugan W, Jr, et al. Zoldedronic acid is superior to pamidronate for the treatment of bone metastases in breast cancer patients with at least one osteolytic lesion. Cancer 2004; 100: 36–43
- Saad F, Gleason D, Murray R, et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J Urol 2003; 169(suppl)394
- Rosen L S, Gordon D, Tchekmedyian N S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613–21
- Body J J, Diel I J, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in t breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–37
- Body J-J, Diel I J, Bell R, et al. Oral ibandronate t improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111(3)306–12
- Body J. Effectiveness and cost of bisphosphonate herapy in tumor bone disease. Cancer Supplement 2003; 7(3)859–65
- Major P P, Lipton A, Berenson J, Hortobagyi G. ral bisphosphonates: A review of clinical use in paents with bone metastases. Cancer 2000; 88(1)6–14